Logo
x

Search

Subscribe Now

RCC

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metast...

  • August 25, 2021
Merck Reports the US FDA's Acceptance of sBLA and Priority Review for Keytruda (pembrolizumab) as an Adjuvant Treatment for RCC

Merck Reports the US FDA's Acceptance of sBLA and Priority Review for Keytruda (pembrolizumab) as an Adjuvant Treatment for RCC

  • August 10, 2021
Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in P-III JAVELIN Renal 101 trial for 1L Advanced Renal Cell Carcinoma (RCC)

Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in P-III JAVELIN Renal 101 trial for 1L Advanced Renal Cell Carc...

  • February 19, 2019
AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3 Study for Refractory Advanced or Metastatic Renal Cell Carcinoma (RCC)

AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3 Study for Refractory Advanced or Metastatic Renal Cell Carcin...

  • February 19, 2019
Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Renal Cell Carcinoma (RCC)

Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Rena...

  • February 18, 2019
Bristol-Myers Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate-214 study in Patients with Advanced or Metastatic RCC

Bristol-Myers Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate-214 study in Patients with Advanced o...

  • February 12, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.